Celldex Therapeutics, Inc. has announced that the first patient has been dosed in their Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). EoE is a chronic inflammatory disease of the esophagus and the most common type of eosinophilic gastrointestinal disease. The study aims to evaluate the efficacy and safety profile of subcutaneous barzolvolimab in patients with active EoE.
The study will include approximately 60 clinical trial centers across 8 countries, including the United States. The primary endpoint of the study is reducing esophageal intraepithelial infiltration of mast cells, while secondary endpoints include the reduction of symptoms of dysphagia and esophageal intraepithelial infiltration of eosinophils and safety.
EoE is characterized by the infiltration of eosinophils in the esophagus, resulting in symptoms such as trouble swallowing, chest pain, vomiting, and impaction of food. Currently, there are limited treatment options for EoE. Several studies have suggested that mast